Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics reported a third-quarter 2026 net loss of $193.55 million, or $1.06 per share, compared with $108.04 million, or $0.76 per share, a year earlier. The wider loss reflected higher research and development and general and administrative expenses as manufacturing and clinical-trial activity increased. The FDA accepted the company’s BLA for z-rostudirsen for exon 51 Duchenne muscular dystrophy for priority review, with a target decision date of January 21, 2027. Dyne also reported ongoing Phase 3 trials for z-rostudirsen and z-basivarsen and the start of a Phase 1 trial for its FSHD program after IND clearance.